https://www.selleckchem.com/products/z-ietd-fmk.html Since December 2019, 414,179 cases of people with coronavirus disease 2019 (COVID-19) have been reported. As a result of the rapid increase in confirmed cases and deaths, population and health personnel, have experienced psychological problems, such as anxiety, depression, and stress. Although scientific information on COVID-19 is constantly increasing, it mainly focuses on genetic, epidemiological aspects, and public health measures, leaving aside possible effects on mental health. In order to summarize the current evidence, we present a narrative review of the effects of the COVID-19 pandemic on mental health. So far, the presence of anxiety, depression, and stress has been reported mostly in general population. Nonetheless, mental health issues have also been reported in health care workers, especially among female professionals, nurses, and those who work directly with suspected or confirmed cases of COVID-19. In efforts to reduce the spread of the disease, attention should be paid to the diagnosis and treatment of mental health issues. We believe that addressing them adequately will empower Peru to contain and eradicate COVID-19.The Instituto de Evaluación de Tecnologías en Salud e Investigación (IETSI) of the Seguro Social de Salud (EsSalud) has completed seven brief reports by means of rapid reviews of evidence regarding the potentially effective therapies against SARS-CoV-2 in order to provide current and relevant information for decision makers, clinicians, researchers and the academic community in Peru. The therapeutic agents evaluated were chloroquine/hydroxychloroquine, lopinavir/ritonavir, tocilizumab, oseltamivir, interferon, atazanavir and anti SARS-CoV-2 serum. Evidence identification included the review of PubMed and Cochrane Library electronic databases. Additionally, manual search was carried out on websites from groups dedicated to research and education on health, as well as in the main specia